Suboxone (buprenorphine/naloxone) is no longer under patent, but a generic version has not yet been marketed. "If one were introduced in the future, it would be likely to lower the cost of buprenorphine treatment, making the drug significantly less expensive than methadone and, possibly, less costly overall than drug-free treatment," wrote Robin ...[Read More]

Under a new White House plan to curtail prescription drug abuse, physicians would receive training in the prescribing of long-acting and extended-release opioids. APA has voiced its support for the plan. Abstract Teaser ...[Read More]